BIG PHARMA NEWS: 10 GLP-1 Patient Announcements This Week (GLP1, Foundayo, Zepbound, Wegovy news!)

Hinzugefügt: 2026-05-06

[00:00:00]Big pharma news. 10 GLP-1 patient announcements this week with GLP-1, Fondeo, Ompic, Wiggoi, and Mjaro. Let's dive into our first story. So, there's a new kid on the block. Um, the Wall Street Journal from April 28th, 2026 titled the Boringer Ingleham. Um, forgive my butchering of that, but it was obesity drug. It's actually going to help patients lose fat rather than muscle. it's in late stage trials. And so that's been one of the biggest things about Osmpic Majaro Wegoi Zeppbound is the muscle mass loss. I lost 28 pounds in my um 113 pound weight loss. And so that's a big deal for people on GLP as GLP1 patients. So there's a summary of the findings in a synchronized one. It's phase three trial of this new drug. And y'all know I love talking about new drugs. Drop a follow down below if you love hearing about new drugs. But it's called servo dutide. It's a dual glucagon GLP-1 agonist. And basically it appears to solve one of the biggest pain points that GLP1 patients have that we find with ozumpic major and trespide semiglutide is muscle wasting. Is that with the new servo dutide? That's how you spell it. Servodide. I may be mispronouncing that and I tried to find how you pronounce it and I could not easily find it. But servo dutide it has selective fat loss. So basically the initial initial data from this synchronize one the phase three trials is it's indicating that the weight reduction was predominantly by a loss of fat tissue um with lean muscle contributing only to a really small proportion of total weight loss. WOOHOO.

[00:01:48]This is great news. Visceral fat reduction. The drug has showed statistically significant reduction in waist circumference. This is a key clinical marker for metabolically harmful visceral fat. That visceral, we've talked about this visceral fat before that surrounds our internal organs. And so the trial was with obesity or overweight weight without type 2 diabetes for over 76 weeks. And so participants lost 16.6%age of their body weight compared to just 3.2% of the placebo group. In addition, roughly 85% of participants um achieved weight loss of at least 5%. So there was a good success rate with that. The Wall Street Journal also is noting that analysts noted that while these numbers are roughly in line with Nova Nordis Wiggoi, they slightly trail behind the maximum number of weight loss seen in Eli Liy Zepbound. Y'all know I have been looking like go- go gadget to find somebody to continue to beat Zepbound. And it's hard. these drugs and the clinical trials are not um however the quality of weight loss that muscle preservation is actually the competitive edge against zepound. So it's in phase three right now of course to be continued. But with this unlike ompic that only targets the one GLP-1 hormone, the servo duts both.

[00:03:06]It's dual GLP1 and glucagon which glucagon is the other one that's in retatride which is GLP1 gip and glucagon. This is just GLP1 and glucagon for the servo tide. Servu tide.

[00:03:23]It sounds like something that should be in a bathroom. So while the GP1 suppresses appetite, the glucagon increases energy expenditure, meaning your calorie burning and acts directly on the liver. So because of this liver health, the glucagon component, bringinger ingham, they're essentially like a we go um Eli Liy or Nova Nordis, the the pharmaceutical company making this is positioning at as the drug doing the breakthrough of MASH metabolic dysfunction associated I forget. It's basically for chronic liver disease. And so this is common with people in obesity. So this is a successful phase three result. Um and it's excuse me it was it's partners with Zealand Pharma. It's forgive me that was incorrect that I just said it's partnered with Zealand Pharma for Boring Englehham. That is that is accurate. Um and it's preparing for regulatory filings. Full data on the study is going to be presented actually at the American Diabetes Association 2026 scientific sessions in early June. That sounds like so much fun. By the way, I would love to be there. Um, let's go to our next story. This is another big one. By the way, you are going to want to stay till my last story. I've got something on aphib if you've got heart issues. Was also talking about cancer and then a new hormone too that I'm so excited about.

[00:04:41]So, stay clutch of pearls for upcoming episodes or upcoming um stories. Story number two is talking about this is exciting in Canada. Our first generic ozic is here but there's a catch. Um there is was in Reuters about can health Canada is approved for the first generic from Dr. Ready's the catch is that while Canada and India are seeing 40 to 90% price drops US patients are still stuck with brand name prices due to patent laws. the pivot with this um FDA compounding crackdown that is happening.

[00:05:18]There's a safe harbor for cheap compounded versions in the US is closing this as the supply stabilizes. So what this means with this generic um drug is produced by Dr. Readyy's laboratory, a major pharmaceutical company based in India. Like the brandame version, the generic is approved for once weekly treatment of type 2 diabetes in adults to help manage blood sugar levels. And so, Health Canada confirmed that this is a complex synthetic version that is pharmaceutically equivalent to a brand name biologic, meeting all safety and efficacy quality standards. Two snaps in a Z formation queen. In addition, significant cost savings in Canada.

[00:06:00]Generic medications typically cost 45% to 90% less than brandame versions. And so what analysts are expecting with this is about 35% of the original cost once um once three or more generic competitors enter the market. So the incoming competition, Health Canada is currently reviewing eight, what did I say? Eight. There's eight other applications for generic semiglutide.

[00:06:25]Notably, the drug maker Sandos has already announced plans to launch its own generic version in Canada by June 2026. Um this follows a similar move in India where copycat versions were introduced in India in March 2026 after patent expirations. However, the US market is expected to remain shielded from these generics for several more years due to stronger intellectual property protections. So um what this means is thousands of Canadians will be paying out of pocket or straining employer benefit plans. The approved represents the massive shift in affordability.

[00:07:04]While this drug is officially labeled um for diabetes, the availability of a lowcost generic semiglutis is expected to significantly alleviate the financial burden of the entire health care system and provide cheaper alternatives for those on medication for off label for weight medica management.

[00:07:25]Okay, this next story is from Vogue.

[00:07:28]Vogue. Vogue. Vogue. Vogue. So, this is from I found this fascinating. Any other Vogue lovers out there? Um, it's about fashions moving backwards. Vogue is slamming GLP1 aesthetics. So, basically the summary of is Vogue did a piece on the modeling industry um and is returning back to ultra thin standards.

[00:07:47]Does the medical benefit of these drugs outweigh the potential damage to body positivity? This is I would love to know your thoughts down below in the comments. Let me know what you think about this. Um the article in Vogue was highlighting this regression trend in high fashion where in the early 2020s we saw a big push for body positivity, body diversity on runways and in print and Vogue reports that progress has stalled or actually reversed. Designers are increasing to the return of this waif or ultra thin because of GLP1s in their editorial shoots. And it even signals a loss of facial volume was previously considered unhealthy. So this new expose um or new article explores quiet pressures within modeling agencies where agents and scouts are reportedly seeing models who previously were curve or midsize categories. Um suddenly appearing they're in sample sizes now.

[00:08:45]So they're switching their categories within modeling and questions whether these med medications have been professionally requirement to stay competitive in the modeling industry for models and moving away from plus-size representation. Vogue raises concerns about the lack of transparency and unlike um eras where models were open about their extreme dieting or smoking to stay thin, GLP1 era is marked with hush culture. This creates a new unobtainable beauty standard where effortless thinness is projected to the public while chemically maintained behind the scenes. And so is this a fashion pivot backward? Um for editors and interview the editors and stylists who were interviewed for this Vogue piece expressed disappointment in the bo body positivity movement over the last decade is being dismantled potentially. They note that this extreme thinness seen in Paris, Milan shows in February 2026 and March 2026 suggests that the industry is using drugs as a tool rather than an era of um rather as a tool to return to an era of exclusion.

[00:09:49]So I found this very interesting of how there have been so many amazing things happening. Um people health health advocates are calling for medication transparency and fashion advertising like how France had that law that it says that if you you need to label if the images were photoshopped that you need to label like medical transparency if people are on medications.

[00:10:14]I say good luck with that. I don't think that that's going to happen. Um but I think that it's an interesting standard of like the ying to the ying. There's so many beautiful amazing things that have happened in GLP1 and that this is one of those um it's interesting byproduct of GLP1's. Okay, let's talk a little bit about um Eli Lilly's bet on AI. Um there is a new strategic partnership. Oh, by the way, one of our besties sent me this article. If this was you, thank you so much for sending this to me. um with stat news, the FDA real-time trials and in it was also in Reuters too talked about that the future isn't just weekly shots. AI is designed so basically Eli Liy bought out Profluent. It was a 2.25 million billion billion with a B dollar deal and Proffluent is an AI biotech. I'm like fascinated by this by the I love AI stuff and hearing about the biotech component of it. And so, Proffluent receives an undisclosed upfront payment and committed um research and development funding. They're eligible for milestone payments to tied to development and commercial success plus tiered royalties on future sales. This is a huge deal by the way. If you have Eli stock, kudos to you. Kudos to you.

[00:11:34]Um, in this in the Reuters article, it talks about the strategic alliances helped to develop the next generation of gene editing therapies. And we've talked about this before about how genes play such a prominent role in obesity management. But having that um gene editing, the ability to edit genes through this AI biotech company is quite fascinating actually. So the partnership focuses on the kilobbased scale of DNA editing which Proffluence AI um CEO Alli Mandini describes as the holy grail of the field. Unlike traditional gene editing tools like it's C R I S P RC CAS9 that's the tool and it's excellent making small snips or fixes to DNA.

[00:12:22]However, in many diseases are caused by hundreds of different mutations across patients. And so what the goal is of using the proffluent AI um designs is re reccombasis.

[00:12:36]It's basically an enzyme that can cut and paste large sections of our DNA. And the companies aim to insert an entire functional genes into the precise location of the genome. This would allow single treatment to fix diseases disease diseases regardless of specific mutation the patient has.

[00:12:57]In addition, um, Proffluent uses large language models, LLMs. They're the same type of AI that's actually behind chatbt by the way, but it's trained for the biological data rather than human language. And so the AI is used to write code for custom enzymes that don't exist in nature but are perfectly tuned to target specific genome locations. And so Eli Liy's role with Profluent design proffluent is going to design and optimize these AI enzymes. And then Eli Liy is going to receive exclusive license to take the most promising candidates that they're finding out of these through clinical trials and eventually to the market. Brilliant. by the way. Um, so what it's signaling with this is Eli Liy is aggressively diversifying its portfolio beyond the dominant position of GLP1 weight loss drugs and oncology. They're investing more in programmable medicine and Eli Liy is actually positioning itself to cure complex hard to treat genetic conditions that currently have no effective um therapies with it. So that's quite exciting. Um, why this matters about the genetic medicine is it's announced that Eli Lilly's acquisition also of Ajax therapy shows that was for $2.3 billion. That shows profits from the current GLP-1 gold rush are being funneled into high techch AI and DNA platforms. Like that's where we're seeing this next round go, which it could eventually lead to permanent genetic cures for metabolic diseases rather than like daily pills or weekly injections by simply just editing our like the copying pasting of the genetics into it. Is that not so fascinating? I find that one of the most fascinating stories. Now, let's talk about the FDA speeding up clinical trials. This is one of the other ones I am super interested in um because I am highly watching Redat True Tide potentially of its approvals once it gets through its clinical trials. Right now it's currently not approved. But this story is interesting from Stat News. It's By the way, you're going to want to stay tuned to my last articles. We're going to be talking about Aphib. We're going to be talking about a bunch of cool stuff. So stay tuned for number nine and number 10 in my 10 patient GLP1 patient announcements today. So what this stat news article from April 28, 2026 is the FDA is launches effort to actually speed up clinical trials using AI. It details a revolutionary shift in how drug safety and efficacy are monitored in the US. So the FDI has launched this pilot program.

[00:15:22]It's called realtime clinical trials, RTCTs.

[00:15:26]And for the first time in 60 years, boooo the agency is moving away from the weight and C model. They're actually where the data is collected for years before being submitted in massive bundle to a system where regul regulators view safety signals and clinical endpoints as the in the cloud as they occur. The pilot has successfully initiated proof of concept with two pharmaceutical giants. Astro Xena which is in phase two trials for a um treatment native mantle cell for lymphoma which is a rare blood um cancer. The FDA has already begun receiving and validating live signals of the study and then Amjen which is conducting the early stage phase 1B for limited small cell lung cancer. So basically the FDA commercial commissioner which is Dr. Marty McCary stated that roughly 45% of drug development time is currently consumed with administrative dead time and paperwork data cleaning manual uh submission prep. But by using these AIdriven platforms specifically provided by health tech paradigm health I'm like I need to go is paradigm health on the stock exchange. I need to go check into that mental note paradigm health. Um identify super responders immediately. They're going to spot dangerous safety signals weeks or months before the company actually would traditionally report them and potentially cut out years of traditional 10 to 12 year drug approval timeline.

[00:16:56]With this, the system uses aggregated signals like tumor response percentages and rates of side effects rather than individual patient records to protect privacy. This allows regulators to make highlevel decisions without handling that sensitive raw data which remains with the trial sponsors. So what's next for this is the request for information, the RFI. The FDA is seeking public and industry input on this project. So, I think you want to pop off, Colleen. You can by May 29th, 2026. Following the comment period, the agency expects more select companies in a broader pilot of August 2026. And then the ultimate goal is eventually to run continuous trials across all phases of development, making us more competitive in the international drug markets, specifically against China.

[00:17:47]That story fascinates me. Okay, next up, Foundo. Foundo.

[00:17:52]Following the achieve the massive achieve four trials that were released last week or yeah that was the data uh within April.

[00:18:02]Um the Eli Lilly move forward this week with former regulatory filings. Fondo is already being sold for weight loss for 149 a month. That's the starting price point by the way. Every single news story references 149. It's actually not.

[00:18:15]If you go to higher doses it's over $300. So, let's keep it factually accurate for these new sources that keep saying Fondeo is 149. It's more than that when you're on the higher dose.

[00:18:24]That's the starting price to loop you in.

[00:18:27]Eli Liy now is looking to fasttrack its approval for type 2 diabetes for defandeo, which if you recall the most famous ranger of all back on my Medicare news story, which was last week, go back and watch that story talking about the Medicare $50 pilot program for part D.

[00:18:43]Fondeo is on that list.

[00:18:45]The reason why this is exciting potentially is it's for type 2 diabetes, not just for weight loss. So for my type two diabetes friends, trust and believe I will be heavily monitoring this new story. Make sure you click the like and follow button so you can see more of it because I'll be the first to report it.

[00:19:01]Or maybe the second and third, but in a really fun way. The filing indicates data shows a 57% lower risk of all cause death compared to insulin making the powerful case for the pill to become the first line treatment for diabetic patients with heart risks. Don't stay tuned. We're going to talk about that heart uh story here. That's going to be story number eight. But meanwhile, story number seven is going to talk about them hormones. Honey, there's this hormone University of Oklahoma. I can't remember if we talked about this last week or not, but I wanted to talk if I didn't talk about I couldn't remember. So, if I didn't talk about it, I wanted to talk about it. It's FGF-21 reverses diabetes in mice, targeting the same part of the brain as ompic. It's called the hindb brain. And it doesn't stop you, but it doesn't stop you from eating. So, instead of suppressing appetite, it ramps up the body's energies body's energy burning. And scientists are calling this the anti-glutiny alternative, helping the body burn calories at a high rate without the nausea associated with GLP1s. So going back over to that hormone um finding this new hormone and more research on it, that's I find this fascinating because then you can do things like run it through the AI that we were talking about earlier that was for genes. But I still find once we know this hormone, then they can start um that opens up a lot. And that came from University of Oklahoma, by the way. So, go Oklahoma friends.

[00:20:27]My son's having a test on Oklahoma today, too, which is random. Um, go Duke on your test. He's literally probably doing it right now. Okay, next. This one I am heavily watching. It's on AIB. I couldn't remember if we talked about this last week or not. I don't think we did because the news just came. It was in the in between of when I released the new story. I am always very concerned about aphib heart issues, stroke things um because my family has a substantial risk for heart disease. So I'm always monitoring these is at the heart rhythm 2026 conference in Chicago research discovered GLP1s reduce aphib. But here's the kicker. It had nothing to do with weight loss. Isn't that crazy? By the way, they analyzed 13,000 patients in a study that found even people who gained weight or lost very little on GLP1s still saw a significant reduction in irregular heartbeats. This is share this information immediately with your friends because it has the the the drugs have a direct electrifying effect on the heart's biolog biological wiring independent of metabolic benefits of being thinner. And so aphib more importantly the reduction of aphib even in patients who lost zero weight this proves for the first times that GLP-1 drugs have a direct protective effect on the heart's electrical system separate from their weight loss benefits. Share that part of this video with your bestie. The time stamp is 2155 block. Share it because that's super fascinating to me. Um if you know anybody who has heart disease, heart issues, or aphib in their family.

[00:22:06]Next story number nine. You're going to want to stay till story number 10. Story number nine is about aspirin. There's a study that was presented at the ASCO gastrointestinal cancer symposium where pitted GLP1's against the healthc care staple which is aspirin. I didn't know this, by the way, but the findings were that patients on GLP-1 have a 36 to 46% less likely to develop colo colonerectile cancer compared to those taking a daily aspirin, which aspirin has been the long gold standard for preventative care in high-risisk patients for the colonerectile cancer.

[00:22:44]colurectile cancer which by the way I learned today fun fact that if you eat 10 more grams of fiber in your diet it actually helps to decrease colorectile cancer by 7 to 10%. Fun fact. Okay, let's keep going. The study found that semiglutide we go and ompic was significantly more effective at this off label protection than trozeptide zeppbound suggesting that not all GLP1s are created equal when it comes to DNA protection of the gut. I question that.

[00:23:12]I'm like I have theories on that that it was not in the study but for me my theories are that people may have more we talked about this two weeks ago in my GLP1 news stories two weeks ago. You can go back and watch those about how there's a genetic link to people who have who barf tremendously there like it's if you have vomiting or barfing the vomiting or nausea let me put on not I shouldn't say barfing vomiting or nausea it's actually a genetic marker where it's significant for you I would question for people um that if part of this with zbound of reason why it was less effective than we go or ompic is because of the side effect component you know the four most common ones are diarrhea, constipation, nausea, vomiting. Um, and there's less like if you compare the two of the semiglutide versus trozepide that zeppon has higher side effects percentages with it. So I question I wonder that's my that's my kind of shopping theory on that um as well. Okay, story number four or excuse story number 10 not number four is there was a healthline article published on April 27th 2026. Mjaro may lead to greater lean body mass than ompic. And so there's two most popular med GLP-p1 medications impact muscle and connective tissue. And so there's a potency trade-off. Monara alreside leads to faster more significant weight loss but appears to cost patients more in terms of muscle preservation when you compare that to ompic semiglutide. And so what they found was through real world digital phenotyping data published by Med Rxiv to track body composition.

[00:24:48]It was tracked over a year is that patients on Majara lost 1.1% more lean body mass than those on OMIC within the first 3 months. And so this gap actually widened to a 2% difference in the first year mark. And so about 10.3% of Majaro patient patients fell into what researchers call the depletive meadow medo bioype. It's defined as losing more than 20% of your total body weight but also more than 5% of their muscle mass.

[00:25:20]Only 6.7% of Ozic users saw this level of muscle depletion. We're going to talk on later today on my live, which by the way I'll have an Amazon live today. I should I'm going to put it in the free encouragement group the links. Um, but there'll be a Amazon live and then also a YouTube live today. Um, what's the date? Wednesday. Today's date is April.

[00:25:39]Yeah, Wednesday, April 29th as I'm filming this. Um, and then on Thursday, April 30th, I may have another YouTube live to be determined. You can go to my main page and see my live schedule. But so, and I'll talk more about for muscle lean muscle mass will be a how you specifically eat to that. But experts suggest that dual hormone approach of majaro targeting both GLP-1 and GIP are so potent at suppressing that appetite that patients may not eat enough protein. Bum bum bum.

[00:26:07]And so that's why it's triggering this higher muscle cannibalism with it. So I found the main takeaway of it is Mjaro is superior for total weight loss reduction and A1C control. OMIC may be safer for patients at high risk of age related muscle loss and they can't commit to heavy resistance training routine. So, which some people can't.

[00:26:27]Um, and so following muscle preservation protocols, we talked about that, I believe, last week, if not two weeks ago, in my GLP1 news story. So, that was a real tour to France, my friends. Lots of exciting stuff happening. Um, if you did not see taking a right turn, my best of bra episode, those leggings on yesterday's episode, I'm literally holding up a pink bra. You can, if you're a dude, maybe not watch that one, but if you're a lady, it has in there new panties, bras, leggings, tops. I went ham. I'm actually going to buy more of those leggings today. They are akin to to me in my opinion to Aloe, which I bought, which are quite expensive, and Athleta, I love Athleta stuff, but the fabric on these leggings, as a I'm so excited, and as a tall person, they actually fit me, too. So, go watch yesterday's episode if you didn't see it. And there's a discount code on there, too. Um, and I literally I spent over $300 of my own money sidebar to get those clothes to test them for you. And I give my honest opinion. One of the tops I'm like, uh, like I need a bigger size. It's a me problem, not a them problem. Make sure you size up because the top kept rolling up. I said that in the video. So, it's like a completely like it's brutally honest. Um, but hopefully helpful.

[00:27:39]Hopefully helpful. And it's a clothing haul, so there's lots of other stuff.

[00:27:42]There's like a blazer in there, too, and shoes and stuff like that.

[00:27:46]I'm trying to think if there's anything else. Um, I felt like there was something else that I'm not telling you. Our Amazon shopping list is updated down below. Um, I feel like I have more to tell you guys today. I'll be doing the Amazon live today that I'm doing is going to be on the Amazon beauty haul. Oh, that's what it is. All of the beauty deals that are actively going on right now. There's some great prices. No one's talking about this. I'm like, uh, I already stocked up on some of my favorite stuff.

[00:28:13]Um, so that's why I'm going to do my Amazon live. So, come join me. If you miss it, you can watch the replay or you can just shop the list. I'll put my Amazon weekly deal list down below and that has the beauty Amazon sales this week. Obviously, those are subject to change that can change within the hour or things get sold out because they're good deals in this economy. Honey, we're saving our coin while looking fabulous.

[00:28:33]Okay, our emoji of the day today is going to be a peach because I was supposed to share with you guys about the clean and elites peach ring. I think I did. Um, did I we talked about this, right? If not, today's emoji of the day is going to be a peach. It tells me that you made it this far in the video is why I do emojis of the day. Clean Simple Eats has a bunch of new stuff that's come out, which is really good. I've gotten most of it and I need to film my full review of all of those, but you can use the discount code clean on those.

[00:29:01]The new Clean Simple Eats. Oh, it's I don't know if I'm supposed to say. I don't know if I'm supposed to tell you guys. I'm going to say it and if if this video part of the video, I'll cut it out. Elizabeth, cut this part out if I'm not allowed to say, but it's for um for the weight training supplement that you take to make muscles. What's that called? Now I sound like an idiot.

[00:29:22]What's clean's new product release?

[00:29:26]Nope.

[00:29:28]Queen is really what is the queen is talking because if you live in Virginia the queen and the king of the UK Prince Char not Prince Charles King Charles is coming to Front Royal Virginia no disrespect to Front Royal Virginia but it is known as the meth capital of Virginia and so I was going to go and I was talking to the count I should not be going but I was very interested in going. I'm like, out of all the places like Winchester is having Apple Blossom here in Virginia. It's the 250th anniversary of America, why are the king and queen coming to Front Royal? No disrespect for my front royal friends, my front royal.

[00:30:08]Maybe because it says royal in the name of the thing. I'm like, there's so many other small towns that are I'm sorry if you live in front Royal.

[00:30:17]I'm not trying to be I've been to Front Royal. I love y'all's river there. I'm not making disrespect. Do you know the main street I'm talking about though?

[00:30:23]You know that those are the math c I digress. This was not at all on my radar to talk about on today's show.

[00:30:29]Heidiom D1 yapper here. Okay, let's loop it back. What are you doing today to move you closer to your goals? I will see you on today's live stream. Um share this video if you've got friends also who are on JLP1 or any of those subcategories too. Um and hopefully tell me down below, are my time stamps appearing? I've been actively trying to work on this. Are they appearing for you guys? you guys asked and hopefully it's delivering. Um, my sweet friends, so emoji of the day is a peach. Be kind to yourself, be kind to others. I'm count shopping. Count my blessing cuz life is delicious. And if you have not checked into today's uh into the group today, go do that. It's free.shop.com/group.

[00:31:04]Everything else is linked down in the description link below. Love you guys.

[00:31:06]I'll see you tomorrow.